Moriah P. Bellissimo

Oct 1, 2023 | jacc.org | Moriah P. Bellissimo |Justin M. Canada |Jennifer Jordan |Amy C. Ladd

Introduction Substantial advancements in detection and treatment for women diagnosed with breast cancer (BC) have improved 5-year cancer-related survival to 90%.1 However, commonly used BC therapies, such as anthracycline-based chemotherapy (anthra-bC) and chest radiotherapy, have cardiotoxic side effects including injury to cardiac myocytes and other cells, increased oxidative stress, and reductions in left ventricular (LV) ejection fraction (LVEF), thereby accelerating the risk for...

Jun 1, 2023 | jacc.org | Moriah P. Bellissimo |Kerryn Reding |Nathaniel O’Connell |Ralph B. D’Agostino

JACC Journals › JACC: CardioOnc › Archives › Vol. 5 No. 3 IntroductionCancer survivors who received anthracycline-based chemotherapy (ANTH) are at increased risk of cancer therapy–related cardiovascular dysfunction and reduced left ventricular ejection fraction (LVEF), contributing to a heightened risk of developing heart failure (HF).